DBV TECHNOLOGIE/S (DBVT) Given Average Rating of “Hold” by Brokerages
Shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) have been given an average rating of “Hold” by the thirteen research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $21.16.
A number of equities analysts have recently issued reports on the company. Zacks Investment Research downgraded DBV TECHNOLOGIE/S from a “hold” rating to a “sell” rating in a research report on Wednesday, November 7th. BidaskClub raised DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a research report on Friday, November 9th. Bank of America dropped their price objective on shares of DBV TECHNOLOGIE/S from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, November 2nd. Finally, Barclays lowered shares of DBV TECHNOLOGIE/S from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $30.00 to $8.00 in a report on Thursday, December 20th.
Several institutional investors and hedge funds have recently made changes to their positions in DBVT. Exane Asset Management boosted its stake in shares of DBV TECHNOLOGIE/S by 30.0% during the 3rd quarter. Exane Asset Management now owns 65,000 shares of the company’s stock worth $1,460,000 after acquiring an additional 15,000 shares in the last quarter. Bailard Inc. boosted its stake in shares of DBV TECHNOLOGIE/S by 57.4% during the 3rd quarter. Bailard Inc. now owns 74,000 shares of the company’s stock worth $1,662,000 after acquiring an additional 27,000 shares in the last quarter. First Midwest Bank Trust Division boosted its stake in shares of DBV TECHNOLOGIE/S by 19.3% during the 3rd quarter. First Midwest Bank Trust Division now owns 163,358 shares of the company’s stock worth $3,669,000 after acquiring an additional 26,372 shares in the last quarter. BlackRock Inc. boosted its stake in shares of DBV TECHNOLOGIE/S by 4.7% during the 2nd quarter. BlackRock Inc. now owns 309,520 shares of the company’s stock worth $5,970,000 after acquiring an additional 14,032 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of DBV TECHNOLOGIE/S during the 3rd quarter worth about $8,512,000. 44.96% of the stock is currently owned by hedge funds and other institutional investors.
About DBV TECHNOLOGIE/S
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Featured Story: What does EPS mean?
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.